Update on the pharmacokinetic aspects of antiretroviral agents: implications in therapeutic drug monitoring.
The observed inter-individual variation in antiretroviral pharmacokinetics (PK) that results in a wide range of drug exposures from fixed-dose regimens has led to increasing interest in the clinical use of therapeutic drug monitoring (TDM) to individualize dosing of antiretroviral therapy (ART). The focus of this review is to provide an overview of literature available to support therapeutic drug monitoring among the current classes of antiretrovirals, suggest patient populations that may benefit from TDM and bring forth some of the limitations that may exist for widespread use of TDM in a traditional clinical setting.
Slish
J C
JC
University at Buffalo School of Pharmacy and Pharmaceutical Sciences, Department of Pharmacy Practice, 315 Cooke Hall, Buffalo, NY 14260, USA. slish@buffalo.edu
Catanzaro
L M
LM
Ma
Q
Q
Okusanya
O O
OO
Demeter
L
L
Albrecht
M
M
Morse
G D
GD
D044966:Anti-Retroviral Agents / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D019540:Area Under Curve; D016903:Drug Monitoring / Q000379:methods* / Q000639:trends; D006678:HIV / Q000187:drug effects; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans
D044966:Anti-Retroviral Agents